Jci_page_head_homepage_01 Jci_page_head_homepage_02
Modulation of T-cell responses to alloantigens by TR6/DcR3
Jun Zhang, Theodora W. Salcedo, Xiaochun Wan, Stephen Ullrich, Bugen Hu, Theresa Gregorio, Ping Feng, Shijie Qi, Huifang Chen, Yun Hee Cho, Yuling Li, Paul A. Moore, Jiangping Wu
Published in Volume 107, Issue 11
J Clin Invest. 2001; 107(11):1459–1468 doi:10.1172/JCI12159
This article Copyright © 2001, The American Society for Clinical Investigation
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4

TR6-Fc and TR6 represses the development of CTL in mice. Spleen cells from 2C transgenic mice were stimulated with mitomycin C–treated BALB/c spleen cells, and cultured for 6 days in the presence of TR6-Fc (20 μg/ml), TR6 (20 μg/ml), or normal human IgG (20 μg/ml). The percentage of lysis of the target P815 cells by the effector CTL at different effector/target cell ratios as indicated was measured with a standard 4-h 51Cr release assay with samples in triplicate. At the effector/target ratios of 10:1 and 3:1, the CTL activity of the human IgG group or the medium group was significantly higher than that of TR6 or TR6-Fc groups. Data of a representative experiment are shown, and a similar result was obtained from an additional experiment. The CTL activities of TR6– or TR6-Fc–treated versus that of medium- or IgG-treated samples were highly different at 10:1 or 3:1 ratio (all P values < 0.01, ANOVA t test).

Copyright © 2011 American Society for Clinical Investigation.
The JCI is the publication of the ASCI, an honor society of physician-scientists.
Copying, redistribution, and other usage policies